Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting — Clinical Trial Site

255 Registered trials

132 Currently recruiting

Organisation

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Location

Amsterdam, Netherlands

Identifier

ORG-100033850

Address

Plesmanlaan 121, 1066 CX, Netherlands

Departments

3381: Radiology & Nuclear Medicine
3403: Medical Oncology
5002; Gastroenterology
5002:Gastroenterology
Anesthesiology
Cancer Institute
Center for Cell Therapy
Center Gynaecology Oncology Amsterdam
Center of Cellular Therapy
Centrum voor Celtherapie
Clinical Pharmacology
Clinical Research Unit
Clinical Research Unit (CRU)
Clinical Research Unit, Department of Medical Oncology
Clinical Trial Service Unit
CRU
CRU MOD
Department of Biometrics
Department of gastrointestinal and liver oncology (MDL)
Department of Medical
Department of medical oncology
Department of Pulmonary Diseases
Department of pulmonary oncology
Department of pulmonology
Department of Surgery
Dept. Dermatology
Division of Medical Oncology, Division of Molecular Oncology & Immunology
ENT
Gastroenterology
Gastrointestinal liver oncology
Gynaecologic oncology
Gynaecologie
Gynaecology
Gynaecology/Oncology
Head and Neck surgery
Heelkunde
HNKI, Antoni van Leuwenhoek,
Internal Medicine
Internal Medicine / Oncology
Internal Oncology
Interne Geneeskunde
interne oncologie
Internist Oncology
Klinische Farmacologie
long departement
Long Oncologie
Longoncologie
Longziekten
Lung Cancer Center and Thoracic Oncology
Lung department
Lung Diseases
Lungcancer and thoraxoncology
M
MDL
Medical Oncology
Medical oncology and clinical pharmacology
Medical Oncology Department
Medical Oncology, Division of Immunology
Medisch Oncologische Disciplines
Medische Oncologie
Medische Oncologische Discipline
MOD
MOD, Thoracic-Oncology
Molecular Oncology and Immunology
N/A
Nederlands Kanker Instituut
Nederlands Kanker Instituut – Antoni van Leeuwenhoek (NKI-AVL)
Neuro Oncology
Neurology
Nucleaire Geneeskunde
Nuclear medicine
Oncolocy
Oncologie
oncology
Phase I Unit
Pneumology
Pulmonary
Pulmonary department
Pulmonary diseases
pulmonary oncology
Pulmonology
pulmonology department
Radiology & Nuclear Medicine
Radiotherapy
Research Facility
Respiratory disease
Respiratory Medicine
surgery
Surgical Oncology
Thoracic Oncology
Thorax oncology
Thoraxoncologie
Urology
Vakgroep Interne Geneeskunde
Vakgroep Urologie

Clinical trials at this site (255)

Search interface

Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting

2024-513627-16-01 Colorectal cancer metastatic 7 2018-03-28
Pre-operative capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric cancer (PANDA) Recruiting

2024-519075-26-00 Primary resectable, histologically confirmed gastric or 4 2018-02-27
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting

2024-513314-35-00 Adenocarcinoma of the Colon or rectosigmoid (considered 4 2017-01-20
Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international r… Recruiting

2024-516196-32-00 breast cancer 5 2017-01-01
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting

2023-506987-15-00 Metastatic Castration-Resistant Prostate Cancer 9 2016-11-17
DRUP trial Recruiting

2023-509152-33-00 Advanced solid tumor 4 2016-07-25
Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase… Ended

2024-517152-34-00 Irresectable peritoneal metastases of colorectal cancer 4 2026-06-19
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended

2025-521681-10-00 Lung Cancer 4 2025-10-02
FTIH study to investigate the safety and preliminary efficacy of the DNA-repair inhibitor GSK4418959 alone or in combination with other anti… Ended

2024-519721-37-00 Neoplasms, Colorectal 7 2025-08-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P… Ended

2024-518171-59-00 Prostate Cancer 11 2025-01-23
A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended

2023-506387-14-00 Advanced Urothelial Carcinoma 7 2024-09-24
Safe Stop ipi-nivo Ended

2024-516938-34-00 Melanoma 5 2024-09-11
Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended

2023-509633-39-00 Advanced solid tumours 7 2024-08-06
[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary origin Ended

2023-505592-69-00 Carcinoma of Unknown Primary 5 2024-07-12
TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended

2023-503312-32-00 Esophageal squamous cell carcinoma 4 2024-06-24
A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended

2022-501234-37-00 Solid Tumours 7 2024-05-07
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Ended

2023-507460-39-00 Adult patients with resectable muscle-invasive urotheli 10 2024-02-15
A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma… Ended

2023-503575-21-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 5 2024-01-23